The challenge that Joint-RPCA tackles is deceptively simple to state and notoriously hard to solve. Microbiome data are compositional, meaning sequencing reflects relative rather than absolute abundances. They are sparse, with many measurements containing zeros or missing values. And they span wildly different scales, because metabolomics, proteomics, and genomics generate numbers in different units and magnitudes. Traditional approaches often sidestep these problems by analyzing each data layer separately, using dimensionality reduction techniques such as principal coordinates analysis on a distance matrix. But doing so treats the data layers as independent and ignores the inherent correlations between modalities sampled from the same ecosystem, such as the production of a specific metabolite by a specific bacterium.

Joint-RPCA, developed by Bianca Cordazzo Vargas, Cameron Martino, Liat Shenhav, and colleagues spanning institutions from New York University to the University of California San Diego, the University of Turku, and Ben-Gurion University, addresses these issues head-on. The method builds on the OptSpace matrix completion framework, assuming that the input data matrices share an underlying low-rank structured component. In practice, this means the dominant biological signal, such as the difference between diseased and healthy individuals, can be captured by a small number of latent factors, even when that signal is embedded in a sea of high-rank biological and technical noise. The authors are careful to clarify that low-dimensional signal refers to the dimensionality of the latent phenotype factor, not the fraction of total variance it explains, a distinction that matters greatly in microbiome settings where disease effects may be subtle relative to interpersonal variation.

Mathematically, the workflow begins by transforming each data modality using a robust centered log-ratio transformation, which handles sparsity and compositionality without requiring imputation or pseudocounts. Then, a joint dimensionality reduction is performed via singular value decomposition optimized on a local manifold. The key architectural choice is that the sample space is estimated jointly across all modalities, while the feature space is estimated individually within each modality. This yields a shared scores matrix for subjects and distinct loadings matrices for features in each omic type. The output includes a joint low-dimensional representation of samples, feature loadings indicating each feature’s contribution to the axes of variation, and a denoised feature-feature covariance matrix that can be interpreted as a multipartite network of cross-modal interactions.

To evaluate the method, the team benchmarked it against widely used microbiome approaches, including PCoA with Bray-Curtis and Aitchison distances and the single-modality RPCA, as well as general-purpose multi-omics tools such as MOFA+, iClusterPlus, intNMF, and multiblock sPLS from mixOmics. Using data-driven simulations anchored in real data from the Integrative Human Microbiome Project, with induced sparsity ranging from 12 percent down to 3 percent observed density, Joint-RPCA consistently recovered inflammatory bowel disease-associated structure more reliably than the alternatives. Classification accuracy improved by up to sixfold in this benchmark setting, and the method showed greater Mahalanobis distances between phenotype centroids and higher PERMANOVA pseudo-F statistics across simulated densities.

Consistency of feature selection proved to be another strength. When the researchers compared the top-ranked metabolomic features identified by Joint-RPCA and MOFA+ along the component most strongly associated with IBD diagnosis, Joint-RPCA showed a 60 to 70 percent median overlap in its selections across train-test splits and sparsity levels, whereas MOFA+ exhibited less than 30 percent overlap. This indicates that Joint-RPCA more stably recovers the shared low-dimensional phenotype-associated signal rather than selecting features that fluctuate with each training set. In purely synthetic simulations with traceable signals, Joint-RPCA reliably ranked the specific features carrying induced signals among its top loadings, while competitors showed variable or inconsistent performance, particularly when signals were weak.

The method also excels at recovering biologically validated cross-modal relationships. In a study of biological soil crusts, thin living layers on arid soil surfaces, roughly 70 percent of the microbe-metabolite relationships following a wetting event had been experimentally validated, providing ground truth for benchmarking. Joint-RPCA correctly assigned positive covariance values between the cyanobacterium Microcoleus vaginatus and all metabolites the isolate was known to release, and these metabolites ranked among the top 40 co-varying molecules out of 85 total. This finding remained robust even when the sequencing data were subsampled from 50 percent dense down to 1 percent dense. Compared with correlation-based approaches and the specialized method MMvec, Joint-RPCA and MMvec both achieved significantly higher true-positive rates, precision, and recall, but Joint-RPCA did so more than 100 times faster.

That speed advantage stems from a fundamental design difference. MMvec estimates conditional probabilities between metabolite abundances and microbial reads on a per-read basis, so its runtime scales linearly with the number of sequencing reads. Joint-RPCA resolves the high-dimensionality challenge by construction and operates on a per-sample basis, so its runtime scales with the number of samples instead. In runtime experiments using the FINRISK study, one of the largest multi-omics microbiome cohorts to date with 7,167 individuals, Joint-RPCA completed analyses in minutes that would take MMvec days. When processing two independent IBD cohorts with multiple omic types, MMvec required pairwise analysis of all omic combinations, and some pairs had to be excluded because runtimes exceeded 24 hours, forcing the researchers to extrapolate. Joint-RPCA processed thousands of samples and features across omic types within seconds to minutes.

Applied to real-world data, the method delivered replicable biological findings. In the iHMP dataset, which includes matched metabolomics, proteomics, viromics, metagenomics, and metatranscriptomics from 135 samples, Joint-RPCA separated IBD from non-IBD subjects across all omic layers with a PERMANOVA pseudo-F of 17.04. It identified cross-modal markers including urobilin metabolites and Klebsiella pneumoniae that aligned with prior iHMP findings, and it succeeded where single-modality RPCA failed, using the context of proteomics, viromics, and metagenomics to reveal disease-associated patterns in metatranscriptomic and metabolomic data that were otherwise invisible. The signal replicated in an independent UCSD cohort of 146 subjects, with a significant correlation of 0.47 between the IBD-associated metagenomic feature rankings of the two cohorts, and it held in a third validation dataset combining IBD patients with 824 controls from the American Gut Project. Across all three datasets, Phocaeicola vulgatus emerged as the top bacterial species associated with IBD, consistent with its experimentally demonstrated production of disease-linked proteases.

The method’s reach extends beyond human disease. Applied to multi-omics data from human cadaver decomposition across three forensic facilities, Joint-RPCA captured the progression of accumulated degree days along its second principal component and identified a universal microbial decomposer network shared across geographically and climatically distinct sites, including fungal taxa such as Yarrowia and Candida and the bacterium Thiopseudomonas alkaliphila, which single-modality analyses missed. In mammalian gut microbiomes spanning 25 species and five omic types, Joint-RPCA amplified weak signals from gas chromatography-mass spectrometry metabolomics, improving classification of host taxonomy and digestive strategy from an AUC-ROC of 0.65 with independently ranked features to 0.88 when features were ranked in the joint context. The authors caution that the method assumes a shared low-dimensional structure across modalities, does not explicitly adjust for confounders, and does not directly model temporal dynamics, and they emphasize that their benchmark results should be read as evidence of performance in the specific scenarios studied rather than a universal ranking of integration tools. Still, with open-source implementations in Python through the gemelli package and in R through the mia Bioconductor package, plus a QIIME2 plugin and Galaxy integration, Joint-RPCA arrives as a practical, scalable tool poised to reshape how microbiome scientists read the interconnected layers of microbial ecosystems.

Subject of Research: A domain-aware multi-omics integration method for systems microbiology that jointly factorizes sparse, compositional microbiome data layers.

Article Title: Joint-RPCA: domain-aware multi-omics integration for systems microbiology

Article References: Cordazzo Vargas, B., Martino, C., Dilmore, A. H., Metcalf, J. L., Burcham, Z. M., Lahti, L., Bektanov, A., Borman, T., Salomaa, V., Niiranen, T., Havulinna, A. S., Gregor, R., Eyal, S., Meijler, M. M., Mizrahi, I., Song, S. J., Bartko, A., Dorrestein, P. C., Morton, J. T., … Shenhav, L. (2026). Joint-RPCA: domain-aware multi-omics integration for systems microbiology. Molecular Systems Biology. https://doi.org/10.1038/s44320-026-00236-3

Image Credits: AI Generated

DOI: 10.1038/s44320-026-00236-3

Keywords: multi-omics integration, microbiome, Joint-RPCA, dimensionality reduction, matrix completion, inflammatory bowel disease, metabolomics, metagenomics, compositional data, microbe-metabolite interactions, systems microbiology, computational biology

Colitis, a form of inflammatory bowel disease characterized by chronic inflammation of the colon, poses significant treatment challenges and impacts millions globally. Traditional therapeutic strategies mainly involve immunosuppression and symptomatic relief but fall short of addressing the underlying mechanisms governing mucosal repair and homeostasis. The current study shifts the focus towards endogenous metabolic regulators influenced by resident microbiota, showing how microbial metabolites can modulate host metabolism to promote intestinal healing.

Indole propionic acid is a lesser-known yet biologically potent bacterial metabolite produced primarily by specific gut commensals. Researchers have long hypothesized the involvement of such small molecules in signaling cascades between microbiota and host tissues. This latest work elucidates how IPA specifically regulates the expression and activity of 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2), a key mitochondrial enzyme driving ketogenesis within intestinal epithelial cells.

Ketogenesis, traditionally associated with hepatic metabolism during fasting states, has recently been recognized for its extrapolation to other tissues, including the gut. Within the intestinal epithelium, ketone bodies act not only as alternative energy substrates but also as signaling molecules influencing inflammation and cellular repair. By enhancing HMGCS2 activity, IPA effectively stimulates ketogenesis, thereby fostering an environment conducive to mucosal regeneration and barrier integrity restoration.

The molecular underpinnings of this pathway involve IPA binding events that alter transcriptional networks within intestinal epithelial cells, leading to upregulated HMGCS2 gene expression. These changes underpin augmented ketone body synthesis, which subsequently exerts anti-inflammatory effects, dampening pathological immune responses inherent in colitis. Consequently, the interplay between microbial metabolites and host metabolic enzymes emerges as a critical determinant of therapeutic outcomes in intestinal inflammation.

In experimental models of colitis, administration of IPA or modulation of gut microbiota composition yielded robust protection against colonic inflammation. Mice treated with IPA demonstrated significant reductions in disease severity, histological damage, and pro-inflammatory cytokine release. These protective effects correlated with enhanced mucosal healing, underscoring the therapeutic potential of targeting microbiota-derived metabolites and their metabolic pathways.

Beyond preclinical models, the study hints at translational implications for human IBD. Analysis of patient samples revealed a consistent decrease in intestinal HMGCS2 expression and ketone body levels during active disease phases, suggesting that impaired microbiota-host metabolic crosstalk contributes to disease progression. Restoring this axis through probiotic or metabolite-based therapies holds promise for more effective and durable interventions against colitis.

Additionally, the research offers insights into the spatial and temporal regulation of gut ketogenesis, emphasizing the role of localized metabolic shifts in orchestrating immune tolerance and barrier function. Intestinal epithelial cells serve as dynamic metabolic hubs capable of sensing microbial signals and adapting their metabolic programs accordingly, a concept that challenges traditional views of tissue metabolism in health and disease.

Mechanistically, the IPA-HMGCS2 pathway integrates with broader metabolic networks involving fatty acid oxidation, mitochondrial biogenesis, and reactive oxygen species management. This integration highlights the multifaceted nature of metabolic regulation within the gut epithelium and its centrality in maintaining mucosal resilience under inflammatory stress.

Furthermore, these findings underscore the critical influence of microbiota composition on host metabolic health, reinforcing the need to consider microbial ecology in disease pathogenesis and treatment. Dysbiosis, characterized by the loss of IPA-producing bacteria, may predispose individuals to heightened susceptibility to colitis by disrupting this protective ketogenesis-driven mechanism.

The discovery also paves the way for novel biomarker development, where circulating or fecal IPA levels could serve as indicators of mucosal health and therapeutic response. Monitoring these metabolites might refine patient stratification and individualized treatment approaches in clinical practice.

Crucially, this study advocates for a paradigm shift towards leveraging host-microbiota metabolic synergies as a frontier in biomedical innovation. Targeting metabolic nodes like HMGCS2 via microbiota-derived compounds holds transformative potential beyond colitis, possibly extending to other inflammatory and metabolic disorders.

Moreover, the implications of this research reach into nutritional sciences, where diet-induced modulation of microbiota composition and metabolite production could complement pharmacological strategies. Nutritional interventions designed to boost IPA levels or sustain HMGCS2 activity might represent adjunctive therapies enhancing mucosal healing and disease remission.

In conclusion, the intricate crosstalk unveiled between microbiota-derived IPA and intestinal ketogenesis via HMGCS2 not only redefines our understanding of mucosal immunometabolism but also heralds a new era of microbiome-centric therapeutics for colitis. As research unfolds, harnessing these endogenous metabolic circuits promises more precise, effective, and lasting interventions for patients burdened by inflammatory bowel diseases.

Subject of Research: The interaction between microbiota-derived indole propionic acid (IPA) and the regulation of intestinal ketogenesis mediated by HMGCS2 in the context of colitis and mucosal healing.

Article Title: Microbiota-derived IPA protects against colitis by regulating intestinal HMGCS2-mediated ketogenesis to facilitate mucosal healing.

Article References:
Zhang, Y., Tu, S., Shao, X. et al. Microbiota-derived IPA protects against colitis by regulating intestinal HMGCS2-mediated ketogenesis to facilitate mucosal healing. Nat Commun (2026). https://doi.org/10.1038/s41467-026-69341-z

Image Credits: AI Generated

Traditional efforts in FMT strain tracking have largely relied on short-read sequencing technologies, which, while powerful, face intrinsic technical constraints. Short reads, typically ranging from 100 to 300 base pairs, enable detection of microbial taxa and some strain resolution but struggle with complex genomic regions and the de novo assembly of complete bacterial genomes from mixed communities. These limitations are particularly pronounced when multiple strains coexist within the same sample, leading to challenges in discerning subtle genomic differences and co-engraftment dynamics. The revolutionary aspect of LongTrack lies in its utilization of long-read sequencing, capable of reading continuous DNA stretches often exceeding tens of thousands of base pairs, dramatically improving genomic assembly and accuracy in strain identification.

In the study, the research team applied LongTrack to six FMT cases involving patients suffering from recurrent C. difficile infections and inflammatory bowel disease. By focusing on the long-read assemblies of the microbiota obtained after transplantation, the researchers identified a total of 648 bacterial strains that had engrafted stably in the recipients’ guts. This represents a significant advance compared to previous short-read methodologies, not only in terms of the number of strains tracked but also the confidence and specificity with which these strains could be characterized. The large-scale application of this approach highlights the potential of long-read metagenomics to serve as a new standard for strain-level microbiome analyses.

A critical strength of the LongTrack method is its capability to differentiate closely related strains with high precision. This is particularly essential in FMT scenarios, where donor stools often contain multiple strains of the same species, and discerning which ones establish residency in the recipient affects understanding of therapeutic efficacy and bacterial competition. The team demonstrated that LongTrack consistently outperformed short-read based approaches, offering unparalleled specificity. This enhanced resolution allows researchers to dissect the microbial ecology of the transplanted gut microbiome with unprecedented clarity, potentially revealing strain-level interactions and colonization patterns that were previously inaccessible.

Moreover, the advantages of long-read sequencing extend beyond mere strain identification. One of the fascinating insights uncovered by this study was the ability to monitor genomic and epigenomic changes of engrafted strains over an extended period. By analyzing samples taken at a remarkable five-year follow-up, the team was able to assess the structural stability and adaptation of bacterial genomes in the recipient environment. They discovered structural variations, including insertions, deletions, and rearrangements, which could be reflective of evolutionary pressures and microbial adaptation to the host gut. This finding opens an exciting window into microbial dynamics that transcends static snapshots, revealing a living and evolving microbial community post-FMT.

Such longitudinal insights are crucial for interpreting how microbial strains persist or evolve in response to host factors, immunity, diet, or interactions with other microbes. The detection of epigenomic signatures, which influence gene expression without altering DNA sequence, further enriches our understanding of microbial adaptability. Monitoring methylation patterns or other epigenetic marks through the high-fidelity data generated by long reads can inform on mechanisms bacteria employ to thrive in the complex gut environment, potentially impacting their metabolic activity, virulence, or resistance profiles.

From a clinical standpoint, these advancements promise to reshape how FMT outcomes are evaluated and optimized. By accurately tracking which strains successfully engraft and remain stable, clinicians and researchers can correlate specific bacterial profiles with therapeutic success or failure. This could pave the way for personalized microbial consortia development, where cultivated strains with desirable traits are selectively administered to maximize efficacy. In addition, the high-resolution monitoring of microbial populations may aid in identifying biomarkers predictive of relapse or adverse effects, thus refining patient management strategies.

The methodological innovations underlying LongTrack also have far-reaching implications beyond FMT. Long-read metagenomics can be instrumental in a variety of microbiome-related fields, including pathogen surveillance, environmental microbiology, and biotechnology. The ability to reconstruct high-quality microbial genomes directly from complex samples without cultivation is a game-changer, enabling discovery and characterization of previously unrecognized strains, genes, and functional pathways. This capacity will undoubtedly accelerate microbiome science and the translation of its findings into tangible benefits.

However, adopting long-read metagenomics is not without its challenges. Historically, sequencing technologies such as those from Pacific Biosciences (PacBio) and Oxford Nanopore Technologies have struggled with higher error rates compared to short reads, as well as higher costs and greater computational demands for data analysis. The present study showcases that advances in sequencing chemistry, bioinformatic tools, and assembly algorithms have mitigated many of these obstacles, delivering robust and reliable data suitable for high-resolution strain tracking. The development of LongTrack is emblematic of this progress, incorporating tailored computational methods to handle complex metagenomic datasets effectively.

The study further emphasizes the importance of integrating multi-omic approaches, combining genomic and epigenomic data to build holistic profiles of microbial populations. Such integrative analyses are critical for unraveling the complex interplay between microbial genomes, host environments, and clinical variables. As microbial therapeutics become increasingly sophisticated, these insights will be vital to inform design and implementation of precision microbiome interventions.

Looking ahead, the adoption of long-read metagenomics could transform not only fundamental research but also clinical microbiology. For instance, routine monitoring of patient microbiomes post-FMT could provide real-time feedback on engraftment dynamics and microbial resilience, aiding timely decision-making. Additionally, detailed strain-level knowledge could facilitate the engineering of synthetic microbial communities tailored for maximum therapeutic benefit. The ability to observe microbial evolution in vivo also raises intriguing questions about how microbial communities stabilize or shift in response to medical treatments, diet, or other lifestyle factors.

In conclusion, the work by Fan and colleagues represents a landmark in microbial strain tracking methodologies, demonstrating the profound advantages of long-read metagenomic sequencing for FMT research. Their innovative LongTrack approach overcomes longstanding barriers posed by short-read methods, enabling accurate, specific, and longitudinal profiling of engrafted bacterial strains. By unveiling the genomic and epigenomic adaptations of microbial residents over a multi-year period, this study offers critical insights into microbial ecology, evolution, and therapeutic potential within the human gut. This breakthrough is poised to make a significant impact on microbiome science and the future of microbial therapeutics, marking an exciting chapter in our quest to harness the gut microbiome for human health.

Subject of Research: Faecal microbiota transplant (FMT) and bacterial strain tracking using long-read metagenomics.

Article Title: Long-read metagenomics for strain tracking after faecal microbiota transplant.

Article References:
Fan, Y., Ni, M., Aggarwala, V. et al. Long-read metagenomics for strain tracking after faecal microbiota transplant. Nat Microbiol (2025). https://doi.org/10.1038/s41564-025-02164-8

Image Credits: AI Generated